Skip to content Skip to footer
Subscribe Now
Top Performing Drug – Perjeta (January Edition)
INSIGHTS+

Top Performing Drug – Perjeta (January Edition)

Shots:   In continuation of our previous series on the Top-Performing Drug of the month, based on 2021 revenue, this month we have selected Perjeta and prepared a curated analysis report for our readers  Perjeta is indicated for the treatment of HER2-positive metastatic breast cancer, neoadjuvant HER2-positive breast cancer, Adjuvant HER2-positive breast cancer PharmaShots presents a concise…
January 30, 2024

Read more

Top Performing Drugs: Proceeding the Series
INSIGHTS+

Top Performing Drugs: Proceeding the Series

Shots: Subsequent to our last year’s series titled “Top Performing Drugs of 2021”, PharmaShots presents a list of 12 high revenue-generating drugs With the ongoing pandemic playing an instrumental role in reshaping the life science industry now and then, it becomes increasingly onerous for the pharmaceutical industry to keep up with the growing global demands…
April 25, 2023

Read more

PharmaShots Interview Janssen’s Alyssa Johnsen Shares Insights on the New Clinical data of Tremfya (guselkumab) Presented at ACR 2021 and Published in Arthritis & Rheumatology
VIEWPOINTS

PharmaShots Interview: Janssen’s Alyssa Johnsen Shares Insights on the New Clinical data of Tremfya (guselkumab) Presented at ACR 2021 and Published in Arthritis & Rheumatology

In an interview with PharmaShots, Alyssa Johnsen, MD, Ph.D., Vice President, Rheumatology and Maternal-Fetal Health Disease Area Leader at Janssen Research & Development shares her views on the P-III DISCOVER-1 & 2 Studies of Tremfya (guselkumab) for the treatment of psoriatic arthritis in ACR 2021 and published in Arthritis & Rheumatology Shots: The P-III DISCOVER-1 & 2 trials evaluate Tremfya (SC) vs PBO in 381 & 739…
January 4, 2022

Read more

Viewpoints_Atray Dixit
VIEWPOINTS

PharmaShots Interview: Coral Genomics’s Atray Dixit Shares Insights on the 2021 Innovation Challenge in Inflammatory Bowel Disease

In an interview with PharmaShots, Atray Dixit, Co-founder & CEO at Coral Genomics share his views on the winner of the $25K inflammatory bowel disease innovation challenge under the collaboration with Lyfebulb and Arena Shots: Lyfebulb and Arena collaborated to discover 2021 Imagining Life Without Limits Challenge to get the solutions for patients with IBD Coral Genomics was selected as…
December 7, 2021

Read more

Viewpoints_Anish Suri
VIEWPOINTS

PharmaShots Interview: Cue Biopharma’s Anish Suri Shares Insights on the Data of CUE-401 Presented at 2021 FOCIS Annual Meeting

In an interview with PharmaShots, Anish Suri, Ph.D., President, and Chief Scientific Officer at Cue Biopharma shared his views on new preclinical data of CUE-401 for the treatment of autoimmune diseases at the 2021 FOCIS Annual Meeting Shots: The company has reported the preclinical data of CUE-401 which can induce & expand regulatory T cells in vitro and in vivo & has the potential to…
October 15, 2021

Read more

Viewpoints_Paula Ragan
VIEWPOINTS

Pharmashots Interview: Paula Ragan Shares Insights on the Data of Mavorixafor in Combination with Ibrutinib Presented at 2021 EHA Annual Congress

In an interview with PharmaShots, Paula Ragan, Ph.D., President, and Chief Executive Officer at X4 Pharmaceuticals shared her views on preliminary efficacy and safety data of Mavorixafor + Ibrutinib in an ongoing P-Ib study to treat waldenström's macroglobulinemia Shots: The ongoing P-Ib clinical trial evaluates the safety & efficacy of mavorixafor + ibrutinib in patients with WM with both MYD88 &…
September 3, 2021

Read more

Load more